Journal
NEUROTHERAPEUTICS
Volume 14, Issue 2, Pages 307-320Publisher
SPRINGER
DOI: 10.1007/s13311-016-0507-6
Keywords
Glioblastoma; GBM; Response Assessment; T1 Subtraction; RANO
Funding
- American Cancer Society (ACS) [RSG-15-003-01-CCE]
- National Brain Tumor Society (NBTS)
- Art of the Brain
- Ziering Family Foundation in memory of Sigi Ziering
- Singleton Family Foundation
Ask authors/readers for more resources
Radiographic endpoints including response and progression are important for the evaluation of new glioblastoma therapies. The current RANO criteria was developed to overcome many of the challenges identified with previous guidelines for response assessment, however, significant challenges and limitations remain. The current recommendations build on the strengths of the current RANO criteria, while addressing many of these limitations. Modifications to the current RANO criteria include suggestions for volumetric response evaluation, use contrast enhanced T1 subtraction maps to increase lesion conspicuity, removal of qualitative non-enhancing tumor assessment requirements, use of the post-radiation time point as the baseline for newly diagnosed glioblastoma response assessment, and treatment-agnostic response assessment rubrics for identifying pseudoprogression, pseudoresponse, and a confirmed durable response in newly diagnosed and recurrent glioblastoma trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available